Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 133 in overweight or obesity
NCT06976372Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of maridebart cafraglutide in obesity (3 arms), sponsored by Amgen. Primary endpoints: Maximum Concentration of AMG 133, Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration of AMG 133 at Day 29 and 2 more. Started Aug 2024; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06976372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976372.